Evidence map›Paper›PMID 31827181›Full record

ArticleScientific reports2019

Overexpression of LAPTM4B-35 is a negative prognostic factor in head and neck squamous cell carcinoma.

Ulana Kotowski, Lorenz Kadletz, Sven Schneider, Felicitas Oberndorfer, Julia Schnoell, Elisabeth Gurnhofer, Lukas Kenner, Trevor Lucas, Gregor Heiduschka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ulana KotowskiDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-8771-3104
Lorenz KadletzDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. lorenz.kadletz@meduniwien.ac.at.
Sven SchneiderDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Felicitas OberndorferDepartment of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Julia SchnoellDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Elisabeth GurnhoferDepartment of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Lukas KennerDepartment of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0003-2184-1338
Trevor LucasCenter for Anatomy and Cell Biology, Department for Cell and Developmental Biology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.
Gregor HeiduschkaDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overexpression of LAPTM4B-35 (lysosomal-associated transmembrane protein 4β-35) is associated with a poor prognosis in numerous malignant tumours. Expression patterns and effects of LAPTM4B-35 on head and neck squamous cell carcinomas (HNSCC) are unknown. The aim of this study was to investigate the prognostic relevance of LAPTM4B-35 in HNSCC. Tissue microarrays were constructed with primary tumours and associated lymph node metastases isolated from 127 patients. The expression of LAPTM4B-35 was investigated by immunohistochemistry and the results were correlated with survival data. LAPTM4B-35 in the primary tumour was highly expressed in 47.2% of the patients (60/127). LAPTM4B-35 expression was significantly associated with tumour stage. Moreover, overexpression of LAPTM4B-35 correlated with a significantly worse disease-free survival (10.23 years vs. not reached) and a higher recurrence rate (40.7% vs. 25%). High expression of LAPTM4B-35 in lymph node metastasis was found in 29.2% of cases. In 19.4% of cases, high LAPTM4B-35 expression was observed in both the primary tumour and corresponding lymph node metastases. In conclusion, our data indicates that overexpression of LAPTM4B-35 is associated with poor prognosis and may therefore serve as a new prognostic marker in HNSCC.

Indexed as

Biomarkers, TumorDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMembrane ProteinsMiddle AgedOncogene ProteinsPrognosisSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorLAPTM4B protein, humanMembrane ProteinsOncogene Proteins

Identifiers

PMID31827181
PMCPMC6906383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.